source
- Novartis' Rhapsido shows safety edge and relapse reduction in Phase 3 multiple sclerosis trialsNovartis reported results from two identical Phase 3 studies of its BTK inhibitor Rhapsido in patients with multiple sclerosis. The trials showed the oral pill lowered the annualized relapse rate…
- ARPA-H grants up to $125M to accelerate on-demand custom RNA therapy manufacturingARPA-H announced a new funding initiative aimed at speeding the creation of personalized RNA medicines. The agency will provide up to $125 million in total awards. Five research groups were select…